This Article Abstract Full Text Full Text (PDF) View Online Appendix View Related Story on Cardiosmart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Suk Danik, J. Articles by Ridker, P. M. Search for Related Content PubMed Articles by Suk Danik, J. Articles by Ridker, P. M. Related Collections Related Articles

Lipoprotein(a), Hormone Replacement Therapy, and Risk of Future Cardiovascular Events

Jacqueline Suk Danik, MD, MPH^_*,,,_*, Nader Rifai, PhD^||, Julie E. Buring, ScD^, and Paul M. Ridker, MD, MPH^_*,,,

^_* Donald W. Reynolds Center for Cardiovascular Research, Brigham and Women's Hospital, Boston, Massachusetts
Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Boston, Massachusetts
Division of Preventive Medicine, Brigham and Women's Hospital, Boston, Massachusetts
Division of Cardiology, Brigham and Women's Hospital, Boston, Massachusetts
^|| Department of Laboratory Medicine, Children's Hospital, Harvard Medical School, Boston, Massachusetts.

View larger version (12K): [in this window] [in a new window] [Download PPT slide]   Figure 1 Cumulative Incidence of Major Cardiovascular Disease According to Lipoprotein(a) Quintiles and Hormone Therapy Status The probability of cardiovascular events according to increasing lipoprotein(a) [Lp(a)] quintile levels were derived separately among women not taking hormone replacement therapy (HT) (left) and among women taking HT at study initiation (right). Quintiles are labeled from 1 to 5, referring to the 1st to 5th quintiles, and were defined separately within the 2 groups of women.